E. Heintjes

First name

E.

Middle name

M.

Last name

Heintjes

Korhonen, P., Heintjes, E. M., Williams, R., Hoti, F., Christopher, S., Majak, M., et al. (2016). Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. Bmj. http://doi.org/10.1136/bmj.i3903

View

Strongman, H., Korhonen, P., Williams, R., Bahmanyar, S., Hoti, F., Christopher, S., et al. (2017). Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2016-000364

View

Strongman, H., Christopher, S., Majak, M., Williams, R., Bahmanyar, S., Linder, M., et al. (2018). Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000481

View

Heintjes, E. M., Bezemer, I. D., Prieto-Alhambra, D., Smits, E., Booth, H. P., Dedman, D., et al. (2020). Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries. Clin Epidemiol. http://doi.org/10.2147/clep.s242065

View